XML 27 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document and Entity Information - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2024
Feb. 28, 2025
Feb. 24, 2025
Jun. 28, 2024
Document Information [Line Items]        
Document Type 10-K      
Amendment Flag false      
Entity Voluntary Filers No      
Entity Well-known Seasoned Issuer Yes      
Document Period End Date Dec. 31, 2024      
Document Fiscal Year Focus 2024      
Document Fiscal Period Focus FY      
Trading Symbol VERA      
Entity Registrant Name Vera Therapeutics, Inc.      
Entity Central Index Key 0001831828      
Current Fiscal Year End Date --12-31      
Entity Current Reporting Status Yes      
Entity Filer Category Large Accelerated Filer      
Entity Interactive Data Current Yes      
Entity Shell Company false      
Entity Small Business true      
Entity Emerging Growth Company false      
Title of 12(b) Security Class A common stock, $0.001 par value per share      
Security Exchange Name NASDAQ      
Entity File Number 001-40407      
Entity Incorporation, State or Country Code DE      
Entity Tax Identification Number 81-2744449      
Document Annual Report true      
Document Transition Report false      
Entity Address, Address Line One 2000 Sierra Point Parkway      
Entity Address, Address Line Two Suite 1200      
Entity Address, City or Town Brisbane      
Entity Address, State or Province CA      
Entity Address, Postal Zip Code 94005      
City Area Code 650      
Local Phone Number 770-0077      
Entity Public Float       $ 1.7
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant’s fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K.

      
ICFR Auditor Attestation Flag true      
Document Financial Statement Error Correction [Flag] false      
Auditor Location San Francisco, California      
Auditor Name KPMG LLP      
Auditor Firm ID 185      
Auditor Opinion

Opinions on the Financial Statements and Internal Control Over Financial Reporting

 

We have audited the accompanying balance sheets of Vera Therapeutics, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations and comprehensive loss, stockholders’ equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024 based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

      
Common Class A [Member]        
Document Information [Line Items]        
Entity Common Stock, Shares Outstanding     63,748,290  
Common Class B [Member]        
Document Information [Line Items]        
Entity Common Stock, Shares Outstanding   0